HEalth and Reproduction obesity medicAtion (HERA) study

  • Research type

    Research Study

  • Full title

    HEalth and Reproduction obesity medicAtion (HERA) study: Exploring injectable weight loss medication and reproductive health

  • IRAS ID

    347641

  • Contact name

    Kate Maslin

  • Contact email

    kate.maslin@plymouth.ac.uk

  • Sponsor organisation

    Royal Cornwall Hospital Trust

  • Duration of Study in the UK

    1 years, 5 months, 0 days

  • Research summary

    Obesity is defined as a high level of body fat that may be harmful to health. Obesity increases the risk of complications for mother and baby during pregnancy and birth. Around a quarter of women and birthing people start pregnancy living with obesity. Obesity rates and pregnancy complications are higher in Black and other ethnic minority groups. It is important that all women and birthing people are supported to be as healthy as possible before pregnancy, which may include losing weight.

    New injectable weight loss medications are available which can make weight loss easier. These medications should not be taken during pregnancy, as they may be unsafe for the baby. However, people are using them to lose weight before pregnancy. These medicines are in high demand. People can get them on prescription in some specialist clinics. People taking these medications should use contraception to prevent pregnancy. We don’t know whether healthcare professionals explain this important advice. We don’t know if everyone getting the medicines online gets this advice.

    The aim of this study is to understand the experiences and needs of women and birthing people aged 18-45 using injectable weight loss medications. We will do this by asking women and birthing people in three different areas to take part in a questionnaire and an individual online interview. We have chosen these locations to be inclusive of people from different backgrounds and experiences. We will feedback the results to the public and clinicians in the swiftest way possible to prevent potential harm from these popular medications. We want the results to be used to design future research to test how best these medications can be used for weight loss before pregnancy, to help women and birthing people have safer and healthier pregnancies.

  • REC name

    South Central - Berkshire Research Ethics Committee

  • REC reference

    26/SC/0029

  • Date of REC Opinion

    22 Jan 2026

  • REC opinion

    Further Information Favourable Opinion